AdvisorShares Investments LLC Purchases Shares of 50,340 DBV Technologies S.A. $DBVT

AdvisorShares Investments LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 1st quarter, Holdings Channel.com reports. The fund acquired 50,340 shares of the company’s stock, valued at approximately $1,052,000.

Other hedge funds also recently modified their holdings of the company. Allworth Financial LP bought a new position in shares of DBV Technologies in the fourth quarter valued at approximately $32,000. Royal Bank of Canada acquired a new position in shares of DBV Technologies in the 4th quarter worth approximately $34,000. GAMMA Investing LLC grew its position in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares during the last quarter. Truvestments Capital LLC increased its holdings in DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in DBV Technologies during the 4th quarter valued at $115,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on DBVT shares. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a research note on Tuesday. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, June 29th. Finally, Citizens Jmp upped their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $15.82 on Friday. DBV Technologies S.A. has a 52-week low of $8.51 and a 52-week high of $26.18. The stock has a market cap of $936.70 million, a PE ratio of -3.55 and a beta of -0.95. The firm’s 50 day moving average price is $17.97 and its two-hundred day moving average price is $19.76.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. As a group, sell-side analysts predict that DBV Technologies S.A. will post -0.38 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.